AbbVie

Open: 162.27 Close: 163.64 Change: 1.37

You don't have read the whole internet to decide whether to invest in AbbVie Company Inc. Use an AI.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, share, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

CVS Health said on Wednesday it will remove Abbvies blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement. AbbVie is projected to report earnings of $2.93 per share, which would represent a year-over-year decline.

Today's News

AbbVie has entered a strategic partnership with Umoja Biopharma for the development of new in-situ chimeric antigen receptor (CAR)-T cell therapy candidates for oncology targets. The partnership comprises two exclusive option and licence agreements. TD Cowen Keeps their Buy Rating on AbbVie (ABBV) Historical Prices for Abbvie Historical Price Change: 0% 0. Average price target includes all analyst analysis. AbbVie expects Botox market share to stay strong despite newer rivals. CVS Health said on Wednesday it will remove Abbvies blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement. AbbVie said late Wednesday it will buy Cerevel Therapeutics for $45 a share, or about $8.7 billion. AbbVie is projected to report earnings of $2.93 per share, which would represent a year-over-year decline of 18.61% Analysts and investors alike will be keeping a close eye on the performance. AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. Learn more about us at www.abbvie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which Abbvie falls in, has gained 8%. For the current quarter, the consensus earnings estimate of $2.93 per share is -18.6% from the year-ago quarter. AbbVie stock has gained 51% since 2020 primarily due to favorable change in price to sales multiple (p/s) The results of a Phase II trial show that Abbvies lutikizumab (ABT-981) 300 mg every other week or 300 mg weekly produced higher response rates. AbbVie Inc. has a Bullish sentiment reading. The company plans to advance the clinical development of lutikizumab in hidradenitis suppurativa to Phase II.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, share, partnership, development, new, target, ABBV, and the most common words in the summary are: abbvie, job, inc, news, stock, get, buy, . One of the sentences in the summary was: CVS Health said on Wednesday it will remove Abbvies blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #job #inc #news #stock #get #buy.